Name

Findcure

Legal name

范恩柯尔生物科技（中山）有限公司

Website

https://findcure-bio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Oncology drug development
• Radiopharmaceutical development
• Tumor immunotherapy
• Kinase inhibitor development
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Daxing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Drug Development & Commercialization: Pre-revenue clinical-stage biotech. Revenue is expected from drug product sales upon regulatory approval. The company aims to develop First-in-Class or Best-in-Class drugs for the global market in oncology immunotherapy and nuclear medicine. Additionally, technology service contracts (e.g., a ~20 million RMB技术服务合同 with Xiuzheng Pharmaceutical in May 2025) generate near-term service revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Findcure is a clinical-stage biopharmaceutical company developing innovative oncology drug candidates through two proprietary technology platforms: (1) the InnoRDC radionuclide drug conjugate (RDC) platform for targeted radiopharmaceuticals, and (2) a tumor immunotherapy platform based on highly selective AXL kinase inhibitors. The company focuses on First-in-Class or Best-in-Class candidates targeting major unmet needs in lung, gastric, pancreatic, esophageal, and urological cancers, and currently has FC084 in Phase II clinical trials plus multiple radiopharmaceuticals in IIT clinical research.

Product overview

Findcure是一家专注于肿瘤免疫和核药两大赛道的创新生物医药企业，拥有三大技术平台：靶向药物设计平台、InnoRDC核素偶联药物平台和硼中子俘获治疗（BNCT）平台。核心产品包括：（1）FC084——国内首个进入临床的高选择性AXL抑制剂，正在开展II期临床联合替雷利珠单抗用于免疫不应答NSCLC；（2）68Ga/177Lu-FC335——靶向FAPα的诊疗一体化核药，完成近50例患者研究；（3）FC614（18F-Bi-PSMA）——前列腺癌诊断核药；（4）多个处于临床前和IIT阶段的核药项目。

Differentiator

Problem solved

Functional benefit

Brands

• 医诺维申 (Yinuoweishen): Wholly-owned subsidiary brand of Findcure, focusing on tumor immunotherapy and radionuclide drug conjugate (RDC) drug discovery and development. Has been certified as a National High-Tech Enterprise and recognized as Zhongshan Innovative Radiopharmaceutical Engineering Technology Research Center.
• InnoRDC

Products and services

• FC084 — Highly Selective AXL Inhibitor First-in-class and best-in-class highly selective AXL receptor tyrosine kinase inhibitor that specifically binds and inhibits the intracellular kinase activation domain of AXL receptors. Remodels the tumor microenvironment, promotes CD8+ T lymphocyte infiltration, reverses immune resistance, and synergizes with PD-1/PD-L1 antibodies, chemotherapy, and TKI drugs. Currently in Phase II clinical trials (combined with tislelizumab) for advanced solid tumors including NSCLC, gastric cancer, liver cancer, breast cancer and sarcoma.
• 68Ga/177Lu-FC335 — FAPα-Targeted Theranostic Radiopharmaceutical FAPα-targeted theranostic radiopharmaceutical covering pancreatic, lung, esophageal, and gastric cancers; same molecule provides both diagnostic imaging and therapeutic killing functionality. Diagnostic 68Ga-FC335 completed ~50 cancer patient IIT studies; therapeutic 177Lu-FC335 completed first patient dosing in therapeutic IIT. Currently in clinical application (IND) stage.
• FC614 (18F-Bi-PSMA) — PSMA-Targeted Diagnostic Radiopharmaceutical

Quantifiable outcome

• FC084 achieved 'good safety and tolerability' in Phase I clinical studies in advanced malignant solid tumor patients
• +3 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and key.

• China General Nuclear Power Isotope and Nanfang Hospital of Southern Medical University (中广核同位素 & 南方医科大学南方医院)coreStrategic or Co-development Partner · 1 May 2025May 2025, three-party joint nuclear medicine laboratory signed at the 27th China Hi-Tech Fair, co-established by CGN Isotope, FindCure, and Nanfang Hospital. The laboratory aims to strengthen FindCure's nuclear medicine R&D and translation platform, leveraging Nanfang Hospital's nuclear medicine department (national key clinical specialty) and CGN's isotope production capabilities.
• China General Nuclear Power Isotope (中广核同位素)coreStrategic or Co-development Partner · 1 December 2024In December 2024, strategic cooperation agreement signed for joint advancement of equity investment, isotope supply, and nuclear medicine industry chain construction. CGN Isotope (a subsidiary of CGN Nuclear Technology Development) is a professional company dedicated to医用同位素 R&D, production and sales, building a complete nuclear medicine industry chain.
• Xiuzheng Pharmaceutical (修正药业)keyStrategic or Co-development Partner · 1 December 2024December 2024 cooperation agreement signed for joint development of BNCT (Boron Neutron Capture Therapy) drug-device combination. May 2025, a technology service contract of ~20 million RMB signed with Xiuzheng Pharmaceutical.
• BeiGene (百济神州)coreStrategic or Co-development Partner · 1 March 2024In March 2024, FindCure and BeiGene reached clinical research cooperation and drug supply agreement to jointly advance FC084 in combination with tislelizumab (百泽安®) for advanced solid tumors. BeiGene provides tislelizumab for the clinical trial; FindCure is the trial sponsor. The Ib/IIa phase clinical trial was approved by CDE in 2024.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Lantheus Holdings: Established radiopharmaceutical company with diagnostic imaging agents (e.g., PYLARIFY for PSMA) and emerging therapeutic pipeline. Broader portfolio competitor with global commercialization infrastructure.
• Novartis (Radioligand Therapy): Global leader in radioligand therapy with approved Pluvicto (Pluvicto/Lutathera franchise) for PSMA and NET tumors. Broad incumbent that defines the commercial benchmark FindCure's theranostic platform is competing against.

Direct peers

• BerGenBio: Clinical-stage oncology biotech focused on AXL kinase inhibition with bemcentinib. Direct peer for FindCure's FC084 AXL inhibitor program, including similar combination strategies with immune checkpoint inhibitors.
• Point Biopharma: Clinical-to-commercial radiopharmaceutical company with PSMA and FAP-targeted programs (acquired by Lilly in 2023). Comparable in clinical-stage radioligand strategy and platform-driven pipeline expansion, illustrating exit multiples for the category.
• ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies with proprietary isotope supply. Comparable to FindCure's theranostic platform strategy and dependence on stable medical isotope supply chains.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic products across PSMA, renal, and oncology indications. Directly comparable to FindCure's theranostic radiopharma business model and InnoRDC platform ambitions.
• Yantai LNC Biotechnology: Chinese radiopharmaceutical company developing diagnostic and therapeutic nuclear medicines including FAP and PSMA programs. Direct domestic peer competing in the same Chinese nuclear medicine market.
• C-Ray Therapeutics: Chinese clinical-stage radiopharmaceutical biotech developing targeted radionuclide therapies for solid tumors. A direct domestic competitor to FindCure's InnoRDC-based FAP/PSMA pipeline in China.

Regional players

• Akeso, Inc. Chinese clinical-stage biotech developing novel immuno-oncology biologics including PD-1/VEGF bispecifics. Comparable as a Chinese-region clinical-stage oncology innovator, though with different modality focus than FindCure's small-molecule/radiopharma dual approach.

Others

• BeiGene: Global oncology biotech and FindCure's strategic partner for tislelizumab supply in FC084 combination trials. As a large oncology player and partner, BeiGene represents both a commercialization pathway and a customer for FindCure's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Findcure